Replies to post #322469 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

The FDA does not make the decision. They advise the company only.

When it comes time to actually evaluate a BLA, then the FDA will decide what they think of such an endpoint change.

NWBO has never said anything on the change. Nor have we seen the update on either clinical trials gov or the German site.